Elevation Oncology (ELEV) 10-Q2024 Q1 Quarterly report

Filed: 2 May 24, 7:01am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. senior Avg

New words: advocated, analyzed, biometric, branch, Budget, Canada, certified, Chinese, copy, Daiichi, domiciled, DPF, Duality, esophageal, exceeded, extinguishment, Florida, Hengrui, Hummingbird, immunotherapy, instrument, ISU, LaNova, LM, MediLink, mental, Merck, modification, monotherapy, neuropathy, neutropenia, Notably, ocular, overexpressed, patritumab, peripheral, poor, retaliation, reversal, statutorily, substantive, Switzerland, SystImmune, unresectable, variation

Removed: ADCC, adjusting, approximate, argued, aspect, attrition, auristatin, authorization, began, Bellina, Bristol, capped, CDC, cleavable, cleaved, compassionate, comprised, confidently, conjugated, consuming, continuation, correction, cytotoxic, DAR, deletion, denial, discover, disincentivizing, dismissed, distancing, domestic, domestically, elderly, expanded, exploring, feasible, Frank, furlough, gastrointestinal, identification, inhibiting, instructed, internalized, Jersey, Jordan, Keymed, leadership, linker, lung, lysosome, mandate, marketplace, matched, Matthew, McLinn, methodology, Michigan, microtubule, MMA, Modernization, molecular, Mongiello, monomethyl, NSCLC, Ohio, origination, outbreak, ovarian, pandemic, passage, passed, passing, payload, peak, penalize, Pennsylvania, post, potent, pre, pro, progressively, promoting, rata, ratio, realign, reconsider, reexamining, regular, renewing, repealed, repealing, responsibility, rethinking, screening, selectively, serving, SOTIO, split, supporting, tiered, transport, travel, Trickett, Turning, unconstitutional, undergoing, unique, unlimited, unnecessary, vulnerability, waiver, Wendler

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ELEV similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Elevation Oncology, Inc. (the “Company”) for the period ending March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Joseph J. Ferra, Jr., President and Chief Executive Officer of the Company, and Tammy Furlong, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of their respective knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.




Dated: May 2, 2024	/s/ Joseph J. Ferra, Jr.
	Joseph J. Ferra, Jr.
	President, Chief Executive Officer and Director (Principal Executive Officer)


Dated: May 2, 2024	/s/ Tammy Furlong
	Tammy Furlong
	Chief Financial Officer (Principal Financial and Accounting Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.